Method for diagnosis and/or prognosis of a septic syndrome

Patent metadata

Field	Value
Publication number	US-11060143-B2
Application number	US-79469006-A
Country	US
Kind code	B2
Filing date	Jan 30, 2006
Priority date	Jan 31, 2005
Publication date	Jul 13, 2021
Grant date	Jul 13, 2021

Abstract

The present invention relates to a method for the diagnosis/prognosis of a septic syndrome based on a biological sample from a patient, characterized in that it comprises the following steps:
a. biological material is extracted from the biological sample, b. the biological material is brought into contact with at least one specific reagent that is selected from specific reagents for the target genes with a nucleic sequence having any one of SEQ ID Nos 1 to 28; c. the expression of at least one of said target genes is determined.

First claim

What is claimed is:

1. A method comprising:
obtaining a blood sample from a patient;
measuring an expression level of a target gene comprising the nucleic acid sequence of SEQ ID NO: 1 in the blood sample obtained from the patient;
performing cluster analysis of the target gene expression level of the patient with expression levels of the target gene from human patients that survived a septic syndrome and expression levels of the target gene from human patients that did not survive a septic syndrome;
determining that the target gene expression level of the patient clusters with the expression levels of the target gene from the patients that did not survive a septic syndrome to identify the patient as having a decreased chance of survival; and
treating the patient having the decreased chance of survival with an antibiotic and/or activated protein C.

2. The method according to claim 1 , further comprising measuring expression levels of target genes respectively comprising the nucleic acid sequences of SEQ ID NOs: 3, 7, 9-15, and 17-28 in the blood sample.

3. The method according to claim 1 , further comprising measuring expression levels of target genes respectively comprising the nucleic acid sequences of SEQ ID NOs: 2, 4-8, 11, and 16 in the blood sample.

4. The method according to claim 1 , further comprising measuring expression levels of target genes respectively comprising the nucleic acid sequences of SEQ ID NOs: 2-28 in the blood sample.

5. The method according to claim 1 , further comprising extracting biological material from the blood sample.

6. The method according to claim 5 , wherein the expression level is measured by contacting the biological material with a reagent specific for an expression product of SEQ ID NO: 1.

7. The method according to claim 6 , further comprising detecting hybridization of the specific reagent to the expression product.

8. The method according to claim 6 , wherein the specific reagent comprises a hybridization probe.

9. The method according to claim 8 , wherein the hybridization probe is immobilized on a substrate.

10. The method according to claim 5 , wherein the biological material comprises nucleic acids.

11. The method according to claim 2 , wherein the expression levels of 22 target genes in the blood sample are measured.

12. The method according to claim 1 , wherein the expression levels of 28 target genes in the blood sample are measured.

13. The method according to claim 4 , wherein no more than 50 specific reagents are used to measure expression levels of the target genes in the blood sample.

14. The method according to claim 1 , further comprising monitoring the expression level of SEQ ID NO: 1 over time.

Assignees

• Pachot Alexandre
• Monneret Guillaume
• Lepape Alain
• Biomerieux Sa

Inventors

• Pachot Alexandre
• Monneret Guillaume
• Lepape Alain

Classifications

• C12Q2600/158

  Expression markers · CPC title

• G01N33/56911

  Bacteria · CPC title

• C12Q1/6883 Primary

  for diseases caused by alterations of genetic material · CPC title

• C12Q2600/118

  Prognosis of disease development · CPC title

• G01N2800/26

  Infectious diseases, e.g. generalised sepsis · CPC title